The following report provide links to a second group of abstracts of papers on prostate cancer given in the abstract listings for the annual meeting of the American Society for Clinical Oncology (ASCO) as “publication only” abstracts but which will not actually be presented at the meeting:
One of these papers is highlit as being of some significant clinical interest:
- Vaishampayan et al. (“Phase II trial of bevacizumab [B] and oral satraplatin [S] and prednisone in docetaxel pretreated metastatic castrate resistant prostate cancer [CRPC]”) have confirmed that satraplatin + bevacizumab + prednisone has clinical activity as second line chemotherapy in men following a docetaxel-based regimen.
- Fabri et al. (“Translational study of the activity of liposomal doxorubicin formulations in hormone-refractory prostate cancer”) report on the potential for use of liposomal doxorubicin in late stage prostate cancer.
- Gomez-Pinillos et al. (“Sequential and intermittent docetaxel [D] and imatinib [Im] in hormone-refractory prostate cancer patients [NYU 04-47]”) have presented additional data on docetaxel and imatinib in HRPC.
- Bedognetti et al. (“An open, randomized, multicentre, phase III trial comparing the efficacy of two tamoxifen [T] schedules in preventing gynecomastia [gy] induced by bicalutamide monotherapy [BM] in prostate cancer patients [pca pts]”) have confirmed that the appropriate dose of tamoxifen to prevent gynecomastia in men receiving bicalutamide monotherapy is 20 mg once daily.
- Calvo et al. (“Use of an inhibitor of differentiation-1 [Id1] expression [exp] to discriminate good prognosis [GP] from poor prognosis [PP] prostate cancer [PCa]“) have developed data suggesting that an inhibitor of differentiation-1 expression may have potential as a prognostic marker for aggressive as opposed to indolent prostate cancer.
- Humphreys et al. (“Impact of age at diagnosis on survival of hormone-refractory prostate cancer (HRPC) patients”) present data suggesting that men < 55 and ≥ 75 years of age at presentation have more aggressive disease, which translates into reduced median and 5-year survival.
- Cetnar et al. (“Phase II study of sorafenib and docetaxel in men with metastatic castration resistant prostate cancer [mCRPC]”) report data suggesting that sorafenib + docetaxel has at least some activity in first-line chemotherapy of metastatic CRPC.
- Fleshon et al. (“Results of a phase II study of carboplatin and etoposide in patients with progressive metastatic castration refractory prostate cancer [mCRPC] and neuro-endocrine differentiation”) have developed data suggesting that the combination of carboplatin + etospide is too toxic to be a viable form of chemotherapy for men with metastatic CRPC.
- Less than surprisingly, Krupski et al. (“Psychosocial impact of prostate cancer surgery on sexual intimacy”) have demonstrated that first-line prostate cancer treatment may be associated with psychosocial problems related to depression, anxiety, and self-esteem that impact sexual relationships.